Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: Distinguishing the forest from the plots

Alzheimer's and Dementia

Volumn 3, Issue 1, 2007, Pages 18-20

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; DEMENTIA; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; HUMAN; META ANALYSIS; METHODOLOGY; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33846133205     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.10.003     Document Type: Note

References (7)

1. Areosa A., Sherriff F., and McShane R. Memantine for dementia. Cochrane Database Syst Rev 3 (2005) CD003154
2. McShane R., Areosa Sastre A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) CD003154
3. McShane R., and Schneider L.S. Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration's systematic review. Alzheimer's Dementia 1 (2005) 67-71
4. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006) 704-715
5. Bakchine S., Pascual-Gangnant L., and Loft H. Presented at 9th Congress of the European Federation of the Neurological Societies (EFNS), September 17-20. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe (2005) Athens, Greece
6. Higgins J., Thompson S., Deeks J., and Altman D. Measuring inconsistency in meta-analysis. BMJ 327 (2003) 557-560
7. Kurz A., Farlow M., Quarg P., and Speigel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 18 (2004) 123-128